Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Intellia Therapeutics to participate in a conference call with JPMorgan » 10:45
12/01/22
12/01
10:45
12/01/22
10:45
NTLA

Intellia Therapeutics

$45.51 /

-5.82 (-11.34%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Cheng holds a conference call with President & CEO Leonard on December 1 at 11 am hosted by JPMorgan. Webcast Link

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$45.51 /

-5.82 (-11.34%)

NTLA Intellia Therapeutics
$45.51 /

-5.82 (-11.34%)

11/14/22 Chardan
Intellia Therapeutics price target raised to $129 from $121 at Chardan
11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
NTLA Intellia Therapeutics
$45.51 /

-5.82 (-11.34%)

  • 01
    Dec
NTLA Intellia Therapeutics
$45.51 /

-5.82 (-11.34%)

NTLA Intellia Therapeutics
$45.51 /

-5.82 (-11.34%)

Syndicate
Intellia Therapeutics 6.55M share Spot Secondary priced at $45.80 » 06:10
12/01/22
12/01
06:10
12/01/22
06:10
NTLA

Intellia Therapeutics

$51.41 /

+3.44 (+7.17%)

The deal size was…

The deal size was increased to $300M from $250M and priced at low end of $45.80-$47.80 range. Goldman Sachs is acting as sole book running manager for the offering.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

11/14/22 Chardan
Intellia Therapeutics price target raised to $129 from $121 at Chardan
11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

  • 01
    Dec
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

Conference/Events
Intellia Therapeutics to participate in a conference call with JPMorgan » 04:55
12/01/22
12/01
04:55
12/01/22
04:55
NTLA

Intellia Therapeutics

$51.41 /

+3.44 (+7.17%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Cheng holds a conference call with President & CEO Leonard on December 1 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

11/14/22 Chardan
Intellia Therapeutics price target raised to $129 from $121 at Chardan
11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

  • 01
    Dec
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

Wednesday
Syndicate
Intellia Therapeutics $250M Spot Secondary; price range $45.80-$47.80 » 17:50
11/30/22
11/30
17:50
11/30/22
17:50
NTLA

Intellia Therapeutics

$51.41 /

+3.44 (+7.17%)

Goldman Sachs & Co.…

Goldman Sachs & Co. is acting as the sole underwriter for the proposed offering.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

11/14/22 Chardan
Intellia Therapeutics price target raised to $129 from $121 at Chardan
11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

  • 01
    Dec
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

Syndicate
Intellia Therapeutics announces $250M common stock offering » 16:41
11/30/22
11/30
16:41
11/30/22
16:41
NTLA

Intellia Therapeutics

$51.41 /

+3.44 (+7.17%)

Intellia Therapeutics…

Intellia Therapeutics announced that it has commenced an underwritten public offering of $250M of shares of its common stock. Goldman Sachs & Co. is acting as the sole underwriter for the proposed offering.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

11/14/22 Chardan
Intellia Therapeutics price target raised to $129 from $121 at Chardan
11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

Over a week ago
Conference/Events
Intellia Therapeutics to participate in a conference call with JPMorgan » 16:51
11/29/22
11/29
16:51
11/29/22
16:51
NTLA

Intellia Therapeutics

$47.97 /

-0.31 (-0.64%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Cheng holds a conference call with President & CEO Leonard on December 1 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$47.97 /

-0.31 (-0.64%)

NTLA Intellia Therapeutics
$47.97 /

-0.31 (-0.64%)

11/14/22 Chardan
Intellia Therapeutics price target raised to $129 from $121 at Chardan
11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
NTLA Intellia Therapeutics
$47.97 /

-0.31 (-0.64%)

NTLA Intellia Therapeutics
$47.97 /

-0.31 (-0.64%)

NTLA Intellia Therapeutics
$47.97 /

-0.31 (-0.64%)

Hot Stocks
EyePoint reports inducement grants under NASDAQ listing rule » 07:02
11/16/22
11/16
07:02
11/16/22
07:02
EYPT

EyePoint

$4.38 /

-0.205 (-4.47%)

EyePoint Pharmaceutical…

EyePoint Pharmaceutical announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 10,700 shares of EyePoint Pharmaceuticals common stock to two new employees. The stock options were granted on November 15, 2022. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $4.42 per share, the closing price of EyePoint Pharmaceuticals' common stock on November 15, 2022.

ShowHide Related Items >><<
EYPT EyePoint
$4.38 /

-0.205 (-4.47%)

EYPT EyePoint
$4.38 /

-0.205 (-4.47%)

08/31/22 Cantor Fitzgerald
Cantor says EyePoint negative stock reaction to 8-K 'overdone'
08/04/22 H.C. Wainwright
EyePoint price target raised to $25 from $24 at H.C. Wainwright
07/07/22 Chardan
EyePoint initiated with a Buy at Chardan
11/16/21 Cantor Fitzgerald
EyePoint stock movement unwarranted, says Cantor Fitzgerald
EYPT EyePoint
$4.38 /

-0.205 (-4.47%)

  • 17
    Nov
Downgrade
Wedbush downgrades Impel Pharmaceuticals to Neutral, lowers price target to $5 » 07:21
11/15/22
11/15
07:21
11/15/22
07:21
IMPL

Impel Pharmaceuticals

$3.37 /

-0.58 (-14.68%)

As previously reported,…

As previously reported, Wedbush analyst Laura Chico downgraded Impel Pharmaceuticals to Neutral from Outperform with a price target of $5, down from $24. The analyst continues to see Trudhesa as a differentiated asset in the migraine space. Nevertheless, commercial traction remains elusive, she argues. With script numbers likely to miss prior full year 2022 guidance and pricing improvements taking longer to materialize, Chico is lowering her Trudhesa revenue estimates. The field force expansion may still increase uptake. However, this brings increased pressure on cash runway, the analyst adds.

ShowHide Related Items >><<
IMPL Impel Pharmaceuticals
$3.37 /

-0.58 (-14.68%)

IMPL Impel Pharmaceuticals
$3.37 /

-0.58 (-14.68%)

11/15/22 Wedbush
Impel Pharmaceuticals downgraded to Neutral from Outperform at Wedbush
08/24/22 JonesTrading
Impel Pharmaceuticals initiated with a Buy at JonesTrading
IMPL Impel Pharmaceuticals
$3.37 /

-0.58 (-14.68%)

IMPL Impel Pharmaceuticals
$3.37 /

-0.58 (-14.68%)

Downgrade
Impel Pharmaceuticals downgraded to Neutral from Outperform at Wedbush » 06:50
11/15/22
11/15
06:50
11/15/22
06:50
IMPL

Impel Pharmaceuticals

$3.37 /

-0.58 (-14.68%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico downgraded Impel Pharmaceuticals to Neutral from Outperform.

ShowHide Related Items >><<
IMPL Impel Pharmaceuticals
$3.37 /

-0.58 (-14.68%)

IMPL Impel Pharmaceuticals
$3.37 /

-0.58 (-14.68%)

08/24/22 JonesTrading
Impel Pharmaceuticals initiated with a Buy at JonesTrading
IMPL Impel Pharmaceuticals
$3.37 /

-0.58 (-14.68%)

IMPL Impel Pharmaceuticals
$3.37 /

-0.58 (-14.68%)

Recommendations
Intellia Therapeutics price target raised to $129 from $121 at Chardan » 16:24
11/14/22
11/14
16:24
11/14/22
16:24
NTLA

Intellia Therapeutics

$53.32 /

-1.66 (-3.02%)

Chardan analyst Geulah…

Chardan analyst Geulah Livshits raised the firm's price target on Intellia Therapeutics to $129 from $121 and keeps a Buy rating on the shares after the company discussed updated phase I dose escalation data on in vivo gene editing asset NTLA-2002 in hereditary angioedema, or HAE. Livshits continues to "be impressed with the translatability of Intellia's in vivo editing program" and believes the results "bode well" for NTLA-2003, the analyst tells investors.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$53.32 /

-1.66 (-3.02%)

NTLA Intellia Therapeutics
$53.32 /

-1.66 (-3.02%)

11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
09/21/22 JPMorgan
JPMorgan starts Intellia with Overweight, adds to Focus List
NTLA Intellia Therapeutics
$53.32 /

-1.66 (-3.02%)

NTLA Intellia Therapeutics
$53.32 /

-1.66 (-3.02%)

NTLA Intellia Therapeutics
$53.32 /

-1.66 (-3.02%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.